Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.47 |
| ▸ | LPL | P06858 | 9/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17143204 | 0.89 | LIPG (0.54) | LIPGLPLPDGFRBKDRP4HB | |
| SCHEMBL29817688 | 0.89 | LIPG (0.54) | LIPGLPLPDGFRBKDRP4HB | |
| SCHEMBL21995592 | 0.88 | LIPG (0.48) | LIPGLPLPDGFRBKDRDGAT1 | |
| SCHEMBL17143231 | 0.88 | LIPG (0.56) | LIPGLPLPDGFRBKDRP4HB | |
| SCHEMBL25540943 | 0.86 | LIPG (0.50) | LIPGLPLPDGFRBKDRPRMT5 | |
| SCHEMBL30973828 | 0.86 | LIPG (0.50) | LIPGLPLPDGFRBKDRPRMT5 | |
| SCHEMBL2618788 | 0.86 | LIPG (0.47) | LIPGLPLPRMT5WDR77P4HB | |
| SCHEMBL29892359 | 0.86 | LIPG (0.47) | LIPGLPLPRMT5WDR77P4HB | |
| SCHEMBL15937417 | 0.85 | LIPG (0.51) | LIPGLPLPRMT5WDR77P4HB | |
| SCHEMBL23349181 | 0.84 | LIPG (0.45) | LIPGLPLPRMT5WDR77P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167072-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230167072-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167072-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | PIEZO1, LEF1, L1CAM | LIPG 1679/4885LPL 1982/4885PDGFRB 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.